Skip Navigation
  Print Page

Research on Prevention of Bilirubin-Induced Brain Injury (BIBI) & Kernicterus: Bench-to-Bedside

Skip sharing on social media links
Share this:

July 21-22, 2003
Hyatt Hotel, Bethesda, Maryland

AGENDA

July 21, 2003

Conference Moderator: Lillian Blackmon, M.D.

OPENING REMARKS

Duane Alexander, M.D., and Tonse Raju, M.D., D.C.H.

SESSION I: NEUROBIOLOGY OF KERNICTERUS

Moderators: Drs. Blackmon and Alexander

  1. Molecular biology, definition and clinical spectrum of bilirubin-induced brain injury. Steven Shapiro, M.D.
  2. Role of neuroimaging in the diagnosis and follow-up of bilirubin-induced brain injury and kernicterus. Robert Zimmerman, M.D.
  3. Kernicterus - A parent's perspective. Susan Sheridan, M.B.A., M.I.M.
  4. Discussion

SESSION II: EPIDEMIOLOGY

Moderators: Lois Johnson, M.D., and Dr. Raju

  1. Epidemiology and sequale of extreme hyperbilirubinemia in the 1990s. Thomas Newman, M.D.
  2. Population based trends in hospital readmission for the treatment of neonatal jaundice in California, 1991-1999. Ciaran Phibbs, Ph.D.
  3. Evidence-based root-cause analysis for bilirubin-induced brain injury and kernicterus. Vinod Bhutani, M.D.
  4. National Children's Study and hyperbilirubinemia. Peter Scheidt, M.D.
  5. Discussion

SESSION III: DIAGNOSTIC METHODS

Moderators: Avroy Fanaroff, M.D., and Linda Wright, M.D.

  1. Non-invasive methods for assessing jaundice and hyperbilirubinemia. Jeffrey Maisels, M.D.
  2. Role of methods to measure bilirubin production and elimination in assessing severe hyperbilirubinemia. David Stevenson, M.D.
  3. Strengths and limitations of specialized techniques for bilirubin measurement: Binding protein, free bilirubin, and total and indirect bilirubin. Antony McDonaugh, Ph.D.
  4. Discussion

SESSION IV: PREVENTION AND TREATMENT STRATEGIES

Moderators: Dr. Maisels and Rosemary Higgins, M.D.

  1. Photobiology of light therapy--unresolved issues. David Lightner, Ph.D.
  2. Experimental and clinical experiences with heme-oxygenase inhibitors in prevention of severe hyperbilirubinemia. Dr. Stevenson
  3. Discussion

July 22, 2003

SESSION V: PUBLIC HEALTH PERSPECTIVES I

Moderators: Mark Klebanoff, M.D., and Marshalyn Yeargin-Allsopp, M.D.

  1. Forthcoming American Academy of Pediatrics (AAP) Clinical Practice Guidelines for the management of jaundice in the newborn infant. Dr. Maisels
  2. Systems-based approach to identifying infants at risk for bilirubin-induced brain damage and /kernicterus: Specificity/sensitivity and usefulness of the hour-specific hyperbilirubinemia nomogram. Dr. Bhutani
  3. Cost-effectiveness of strategies for managing hyperbilirubinemia and preventing kernicterus. Ron Keren, M.D.
  4. Discussion

SESSION VI: PUBLIC HEALTH PERSPECTIVES II

Moderators: Drs. Scheidt and Gabriel Escobar, M.D.

  1. Public health surveillance and developing registries to monitor bilirubin-induced brain injury/kernicterus in a society. Dr. Yeargin-Allsopp
  2. Implementing public policy into clinical practice. Heather Palmer, M.B.B.Ch.
  3. Discussion

SESSION VII: SUMMARY

Moderators: Drs. Blackmon and Fanaroff

  1. Summary Presentations
  2. Neurobiology: Dr. Raju
  3. Epidemiology: Dr. Escobar
  4. Laboratory methods: Dr. Higgins
  5. Phototherapy: Drs. Maisels & McDonaugh
  6. Pharmacological Agents: Debra Birenbaum, M.D.
  7. Systems-based prevention issues/Registry Update: Ann Stark, M.D.
  8. Surveillance and other public health policy issue: Dr. Scheidt

Speakers, Moderators, and Other Participants (Alphabetically by last name):

  • Duane Alexander, M.D. (NICHD, Bethesda, Maryland);
  • Vinod K Bhutani, M.D. (University of Pennsylvania, Philadelphia, Pennsylvania);
  • Debra Birenbaum, M.D. (U.S. Food and Drug Administration, Rockville, Maryland);
  • Lillian Blackmon, M.D. (University of Maryland, Baltimore, Maryland);
  • Charlotte Catz, M.D. (NICHD, Bethesda, Maryland);
  • Nancy Chescheir, M.D. (NICHD, Bethesda, Maryland);
  • Gabriel Escobar, M.D. (Kaiser Division of Research, Oakland, California);
  • Avroy A. Fanaroff, M.D. (Rainbow Babies and Children's Hospital, Cleveland, Ohio);
  • Nancy Green, M.D. (March of Dimes, White Plains, New York);
  • Stephen Groft, Pharm. D. (NIH, Bethesda, Maryland);
  • James Hanson, M.D. (NICHD, Bethesda, Maryland);
  • Thomas Hegyi, M.D. (The University of Medicine and Dentistry of New Jersey [UMDNJ]-Robert Wood Johnson Medical School, New Brunswick, New Jersey);
  • David Heppel, M.D. (Health Resources and Services Administration, Rockville, Maryland);
  • Rosemary Higgins, M.D. (NICHD, Bethesda, Maryland);
  • Deborah Hirtz, M.D. (National Institute of Neurological Disorders and Stroke, Bethesda, Maryland);
  • John Ilekis, Ph.D. (NICHD, Bethesda, Maryland);
  • Lois Johnson, M.D. (University of Pennsylvania, Philadelphia, Pennsylvania);
  • Satish Kalhan, M.D. (Case Western Reserve University, Cleveland, Ohio);
  • Ron Keren, M.D. (The Children's Hospital of Philadelphia, Philadelphia, Pennsylvania);
  • Mark Klebanoff, M.D. (NICHD, Bethesda, Maryland);
  • Benjamin Levinson, M.D. (WellSpring Pharmaceutical Corporation, Neptune, New Jersey);
  • David Lightner, Ph.D. (University of Nevada, Reno, Nevada);
  • Donald Mattison, M.D. (NICHD, Bethesda, Maryland);
  • Diane Madlon-Kay, M.D. (American Academy of Family Physicians, St. Paul, Minnesota);
  • Jeffrey Maisels, M.D. (William Beaumont Hospital, Royal Oak, Michigan);
  • Paul J. Marangos, Ph.D. (InfaCare Pharmaceutical Corporation, Carlsbad, California);
  • Antony F. McDonagh, Ph.D. (University of California, San Francisco [UCSF], San Francisco, California);
  • Thomas B. Newman, M.D. (UCSF, San Francisco, California);
  • Barbara Ostfeld, Ph.D. (UMDNJ-Robert Wood Johnson Medical School, New Brunswick, New Jersey);
  • Susan Pagliaro, B.S. (NICHD, Bethesda, Maryland);
  • R. Heather Palmer, M.B.B.Ch. (Center for Quality of Care Research and Education, Boston, Massachusetts);
  • Ciaran Phibbs, Ph.D. (VA Medical Center, Menlo Park, California);
  • Tonse N. K. Raju, M.D., D.C.H. (NICHD, Bethesda, Maryland);
  • Warren Rosenfeld, M.D. (Winthrop-University Hospital, Mineola, New York);
  • Peter Scheidt, M.D. (NICHD, Bethesda, Maryland);
  • Paul Schyve, M.D. (Joint Commission on Accreditation of Health Care Organizations, Oakbrook Terrace, Illinois);
  • Steven Shapiro, M.D. (Medical College of Virginia, Richmond, Virginia);
  • Susan Sheridan, M.B.A., M.I.M. (Parents of Infants and Children with Kernicterus, PICK, Chicago, IL);
  • Catherine Spong, M.D. (NICHD, Bethesda, Maryland);
  • Ann Stark, M.D. (Harvard Medical School, Wellesley, Massachusetts);
  • David Stevenson, M.D. (Stanford University, Palo Alto, California);
  • Siva Subramanian, M.D. (Georgetown University, Washington, DC);
  • Hendrik J. Verman, Ph.D. (Stanford University, Stanford, California);
  • Ronald J. Wong, Ph.D. (Stanford University, Stanford, California);
  • Linda Wright, M.D. (NICHD, Bethesda, Maryland);
  • Sumner Yaffe, M.D. (University of California, Los Angeles, Los Angeles, California);
  • Marshalyn Yeargin-Allsopp, M.D. (Centers for Disease Control and Prevention, Atlanta, Georgia); and
  • Robert Zimmerman, M.D. (University of Pennsylvania, Philadelphia, Pennsylvania).
Last Updated Date: 11/30/2012
Last Reviewed Date: 11/30/2012
Vision National Institutes of Health Home BOND National Institues of Health Home Home Storz Lab: Section on Environmental Gene Regulation Home Machner Lab: Unit on Microbial Pathogenesis Home Division of Intramural Population Health Research Home Bonifacino Lab: Section on Intracellular Protein Trafficking Home Lilly Lab: Section on Gamete Development Home Lippincott-Schwartz Lab: Section on Organelle Biology